1-8 of 8
Weiyuan Chung
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Hans C. Lee, Rafat Abonour, Sikander Ailawadhi, Brian G.M. Durie, Cristina J. Gasparetto, James W. Hardin, Mohit Narang, James Omel, Robert M. Rifkin, Howard Terebelo, Kathleen Toomey, Lynne I. Wagner, Samantha Slaff, Dailan Danforth, Weiyuan Chung, Jasmeet Anand, Edward Yu, Derek Tang, Sundar Jagannath
Journal: Blood
Blood (2022) 140 (Supplement 1): 13256–13258.
https://doi.org/10.1182/blood-2022-158197
Published: 2022
Journal Articles

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD FRCPC, Christopher S. Seet, MD PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz, III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-134189
Published: 2020
Journal Articles

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

David S Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V Matous, MD, Kevin Song, MD, Christopher S. Seet, MD, Giampaolo Talamo, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand Anz, MD, Gustavo Fonseca, Donna Reece, Amit Agarwal, MD PhD, Weiyuan Chung, Faiza Zafar, MPAS, Nizar Bahlis, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3271.
https://doi.org/10.1182/blood-2018-99-111920
Published: 2018
Journal Articles

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

William E. Pierceall, Nizar Bahlis, MD, David S Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V Matous, MD, Kevin Song, MD, Christopher S. Seet, MD, Giampaolo Talamo, Shanti Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand Anz, Gustavo Fonseca, Donna Reece, Weiyuan Chung, Natalya Serbina, Faiza Zafar, MPAS, Amit Agarwal, MD PhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2012.
https://doi.org/10.1182/blood-2018-99-111554
Published: 2018
Journal Articles

Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint

Aaron Seth Rosenberg, MD, Thierry Facon, MD, Safiya Abouzaid, MPH, PharmD, Shankar Srinivasan, PhD, Weiyuan Chung, Kejal Parikh, BSPharm, MS, Joseph Tuscano, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3113.
https://doi.org/10.1182/blood.V130.Suppl_1.3113.3113
Published: 2017
Journal Articles

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

David Siegel, MD PhD, Gary J. Schiller, MD, Kevin W Song, MD, Richy Agajanian, Ketih Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Christy Samaras, Ehsan Malek, MD, Giampaolo Talamo, Christopher S. Seet, Jorge Mouro, MS, Faiza Zafar, MPAS, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Amit Agarwal, MD PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1812.
https://doi.org/10.1182/blood.V130.Suppl_1.1812.1812
Published: 2017
Journal Articles

Comparative Analysis of Clinical Trial Outcomes between African American and White Patients Treated with Lenalidomide and Dexamethasone for Multiple Myeloma (MM)

Sikander Ailawadhi, Gail Larkins, RN, MBA, Weiyuan Chung, Shankar Srinivasan, PhD, Amit Agarwal, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3428.
https://doi.org/10.1182/blood.V130.Suppl_1.3428.3428
Published: 2017
Journal Articles

Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety

David S. Siegel, MD PhD, Gary J. Schiller, MD, Kevin W. Song, MD, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Fred J. Reu, Ehsan Malek, MD, Jorge L Mouro, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Syed Rizvi, Anjan Thakurta, PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2016) 128 (22): 4497.
https://doi.org/10.1182/blood.V128.22.4497.4497
Published: 2016